Condition

Lupus Nephritis (LN) clinical trials and research

• 21Clinical trials
• 10Countries

Newest Lupus Nephritis (LN) clinical trials

All recruiting trials (21)

• TranspoCART19 CAR-T therapy in adults with refractory lupus nephritis

  This trial tests whether a patient’s own CD19 CAR-T cells can be safely given and potentially help adults with lupus nephritis that isn’t responding to standard treatments.

  Recruiting Phase 1/2 Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · Badalona, Barcelona and 7 other locations · NCT07799116

• Lupus Nephritis Care Pathway

  A small group of adults with lupus nephritis will try a team-based care path that uses telemedicine and pharmacist-led support to help manage their treatment and see if it improves adherence and outcomes.

  Recruiting Duke University · Durham, North Carolina · NCT07783152

• Initial glucocorticoid-dose harmonization in childhood lupus nephritis

  This trial tests whether starting children with Lupus Nephritis on a lower or higher prednisone dose makes a difference in treatment outcomes.

  Recruiting at 2 sites Phase 4 Peking Union Medical College Hospital · Beijing, Beijing Municipality and 7 other locations · NCT07719140

• See if empagliflozin helps kidney function in people with lupus nephritis

  This study tests whether adding empagliflozin to standard care improves kidney function in adults with active lupus nephritis.

  Recruiting Phase 4 Beni-Suef University · Banī Suwayf · NCT07700940

• HB2198 for adults with moderate to severe lupus, including lupus nephritis and extra‑renal lupus

  This trial will test whether two intravenous doses of HB2198 can safely reduce B cells and improve disease measures in adults with moderate to severe lupus, including lupus nephritis and extra‑renal lupus.

  Recruiting Phase 1 Hinge Bio · Brisbane · NCT07491900

• HSK39297 tablets for lupus nephritis

  This trial will test whether once-daily oral HSK39297 (200 mg or 300 mg) is safe and well tolerated compared with placebo in adults with active lupus nephritis.

  Recruiting Phase 2 Haisco Pharmaceutical Group Co., Ltd. · Nanjing, Jiangsu · NCT07363460

• Comparing two biologic induction regimens and standard mycophenolate therapy for active proliferative lupus nephritis over six months

  This trial will test whether biologic induction therapy with belimumab or telitacicept leads to better kidney responses over six months than standard mycophenolate-based treatment in people aged 14–65 with active proliferative lupus nephritis.

  Recruiting Phase 2 Nanjing University School of Medicine · Nanjing, Jiangsu · NCT07340463

• A CAR-T therapy for hard-to-treat systemic lupus with or without lupus nephritis

  This phase 2a study tests a single infusion of ICG318 CAR-T cells in adults and eligible teens with refractory SLE, with or without lupus nephritis.

  Recruiting Phase 2 iCell Gene Therapeutics · Chicago, Illinois and 3 other locations · NCT07328581

• Dapagliflozin added to standard care for active lupus nephritis

  A 12-week pilot trial will test whether adding dapagliflozin to standard lupus nephritis treatment helps people with active disease.

  Recruiting at 2 sites Phase 4 Brigham and Women's Hospital · Boston, Massachusetts and 1 other locations · NCT07323524

• YTS109 cell therapy for relapsed or refractory autoimmune diseases

  This will try a single infusion of YTS109 immune cells to see if they are safe and help adults 18–65 with relapsed or refractory lupus (including lupus nephritis), Sjogren's syndrome, inflammatory myopathy, or ANCA‑associated vasculitis.

  Recruiting Phase 1 China Immunotech (Beijing) Biotechnology Co., Ltd. · Bengbu · NCT07236762

• YTS109 cell therapy for relapsed/refractory autoimmune diseases

  This trial will try a single infusion of YTS109 immune cells to see if they are safe and help adults aged 18–65 with relapsed or refractory autoimmune diseases such as lupus, Sjogren’s syndrome, inflammatory myopathy, or ANCA-associated vasculitis.

  Recruiting Phase 1 China Immunotech (Beijing) Biotechnology Co., Ltd. · Tianjin · NCT07123519

• ONT01 for Lupus Nephritis and Systemic Lupus Erythematosus

  We will test whether ONT01 is safe and helps adults with lupus nephritis or active SLE when added to standard medicines like mycophenolate.

  Recruiting Early Phase 1 Hospital for Special Surgery, New York · New York, New York · NCT07107659

• YTS109 cell therapy for relapsed or refractory autoimmune diseases

  This trial will try a single infusion of YTS109 cells to see if they are safe and help adults (18–65) with relapsing or refractory autoimmune diseases such as SLE, lupus nephritis, systemic sclerosis, inflammatory myopathy, or ANCA-associated vasculitis.

  Recruiting Phase 1 China Immunotech (Beijing) Biotechnology Co., Ltd. · Hefei, Anhui · NCT07104721

• HLX79 with rituximab (HLX01) for active glomerulonephritis

  This trial will test whether adding HLX79 at different doses to rituximab (HLX01) helps adults with active membranous nephropathy or lupus nephritis.

  Recruiting Phase 2 Shanghai Henlius Biotech · Beijing and 16 other locations · NCT07038382

• Increasing doses of bispecific antibodies for adults with lupus nephritis

  This research will try different doses of bispecific antibody medicines in adults with lupus nephritis to see if they are safe and tolerable over long-term follow-up.

  Recruiting at 20 sites Phase 1 Regeneron Pharmaceuticals · San Francisco, California and 19 other locations · NCT06975787

• Lupus patient registry for better understanding and care

  This study is collecting information from adults with lupus to help improve understanding and care for the disease.

  Recruiting Lupus Foundation of America · Washington D.C., District of Columbia · NCT06927219

• CAR T-cell therapy for patients with relapsed or refractory lupus

  This study is testing a new CAR T-cell therapy to see if it can help people with lupus who haven't found relief from other treatments.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT06902844

• CART19 treatment for lupus in young patients

  This study is testing a new treatment called CART19 to see if it can help young people aged 12-29 with tough-to-treat lupus feel better and improve their health.

  Recruiting Phase 1/2 Children's Hospital of Philadelphia · Philadelphia, Pennsylvania · NCT06839976

• Long-term outcomes for patients with lupus nephritis in China

  This study looks at how well people with lupus nephritis in China do over the long term to see if their kidney health and survival rates have improved since their diagnosis.

  Recruiting First Affiliated Hospital, Sun Yat-Sen University · Guangzhou, Guangdong · NCT06682507

• Using CD19 CAR T cells to treat refractory systemic lupus erythematosus

  This study is testing if a new type of immune cell therapy can help people with hard-to-treat systemic lupus erythematosus feel better.

  Recruiting Phase 1/2 Beijing GoBroad Hospital · Beijing, Beijing Municipality · NCT06585514

• ADX-097 in IgA Nephropathy, Lupus Nephritis, or C3 Glomerulopathy

  This phase 2 study tests whether subcutaneous ADX-097 can be safely tolerated and show clinical activity in people 16 or older with IgAN, LN, or C3G.

  Recruiting at 3 sites Phase 2 Akebia Therapeutics · Hollywood, Florida and 3 other locations · NCT06419205

Related topics

Quick answers

How many Lupus Nephritis (LN) clinical trials are recruiting right now?

21, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 10 countries. The most sites are in China (10 trials), United States (8 trials), Spain (2 trials), Brazil (1 trial), France (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 5, Phase 1: 5, Phase 1/2: 3, Phase 4: 3. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →